Topcon
7732
TEMONA
3985
Forside
2330
Okamoto Glass
7746
Delta-Fly Pharma
4598
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 41.69%555.07B | -17.13%1.83T | -1.97%547.29B | -0.89%463.66B | -39.68%427.83B | -17.29%391.75B | 10.24%2.21T | -1.15%558.3B | -7.63%467.83B | 47.62%709.24B |
Cost of revenue | 26.86%291.05B | -18.32%1T | -5.03%291.18B | -8.48%241.55B | -37.50%238.1B | -16.00%229.43B | 12.15%1.22T | -0.73%306.61B | -3.49%263.93B | 41.87%380.96B |
Gross profit | 62.66%264.02B | -15.66%830.27B | 1.76%256.12B | 8.93%222.11B | -42.21%189.73B | -19.06%162.31B | 7.96%984.41B | -1.66%251.69B | -12.49%203.9B | 54.89%328.29B |
Operating expense | 23.05%98.29B | 2.00%374.01B | 12.12%110.89B | 0.59%89.65B | -2.15%93.58B | -3.77%79.88B | 17.32%366.68B | 13.21%98.9B | 15.81%89.13B | 20.93%95.64B |
Staff costs | ---- | 20.25%43.39B | ---- | ---- | ---- | ---- | --36.08B | ---- | ---- | ---- |
Research and development costs | 22.45%53.44B | 6.11%202.87B | 8.62%58.41B | 7.97%49.79B | 3.76%51.04B | 3.60%43.64B | 20.81%191.2B | 21.76%53.77B | 19.62%46.11B | 19.42%49.19B |
Other operating expenses | 23.76%44.85B | -8.36%127.75B | 0.52%9.1B | -7.33%39.86B | -8.41%42.54B | -11.36%36.24B | -9.65%139.41B | -79.04%9.05B | 11.98%43.02B | 22.57%46.45B |
Operating profit | 101.05%165.73B | -26.14%456.26B | -4.95%145.23B | 15.41%132.46B | -58.67%96.14B | -29.86%82.43B | 3.08%617.73B | -9.37%152.79B | -26.45%114.77B | 75.11%232.65B |
Net non-operating interest income (expenses) | 107.85%2.57B | 100.49%1.24B | ||||||||
Non-operating interest income | ---- | 107.85%2.57B | ---- | ---- | ---- | ---- | 100.49%1.24B | ---- | ---- | ---- |
Net investment income | 76.88%-307M | -196.07%-4.15B | -108.26%-1.34B | -159.36%-317M | -97.63%-1.17B | -88.90%-1.33B | 5.85%-1.4B | -790.32%-642M | 122.76%534M | -197.20%-590M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | 14.07%843M | 14.15%3.39B | 1.44%987M | 47.80%739M | 72.46%2.97B | 133.33%973M | 79.18%783M | 155.20%712M | ||
Special income (charges) | -368.75%-150M | 3,216.41%10.25B | 1,462.11%10.64B | 60.46%-240M | 68.08%-113M | 34.69%-32M | 93.45%-329M | 418.22%681M | -500.99%-607M | -210.53%-354M |
Less:Other special charges | 368.75%150M | -9,306.42%-10.25B | -1,462.11%-10.64B | 42.01%240M | -68.08%113M | -34.69%32M | -102.17%-109M | -418.22%-681M | 67.33%169M | 210.53%354M |
Less:Write off | ---- | --0 | --0 | ---- | ---- | ---- | --438M | --0 | ---- | ---- |
Other non-operating income (expenses) | -6.07%1.13B | 9.74%5.11B | -136.75%-222M | -94.64%44M | 43.01%4.09B | 220.53%1.2B | 190.89%4.66B | 144.31%604M | -44.64%821M | 105.90%2.86B |
Income before tax | 101.47%167.25B | -24.23%473.44B | 1.43%157.86B | 15.60%134.44B | -58.29%98.12B | -29.44%83.01B | 4.72%624.86B | -7.43%155.64B | -25.22%116.3B | 74.26%235.27B |
Income tax | 119.56%41.06B | -28.57%109.48B | -10.97%32.92B | 7.11%32.91B | -55.48%24.94B | -36.71%18.7B | -3.98%153.27B | -10.47%36.98B | -32.46%30.73B | 59.33%56.02B |
Net income | 96.21%126.19B | -22.82%363.96B | 5.29%124.94B | 18.65%101.53B | -59.18%73.18B | -27.00%64.31B | 7.90%471.58B | -6.44%118.66B | -22.22%85.57B | 79.51%179.25B |
Net income continuous operations | 96.21%126.19B | -22.82%363.96B | 5.29%124.94B | 18.65%101.53B | -59.18%73.18B | -27.00%64.31B | 7.90%471.58B | -6.44%118.66B | -22.22%85.58B | 79.51%179.25B |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 96.21%126.19B | -22.82%363.96B | 5.29%124.94B | 18.65%101.53B | -59.18%73.18B | -27.00%64.31B | 7.90%471.58B | -6.44%118.66B | -22.22%85.57B | 79.51%179.25B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 96.21%126.19B | -22.82%363.96B | 5.29%124.94B | 18.65%101.53B | -59.18%73.18B | -27.00%64.31B | 7.90%471.58B | -6.44%118.66B | -22.22%85.57B | 79.51%179.25B |
Gross dividend payment | ||||||||||
Basic earnings per share | 98.76%273.22 | -22.23%783.75 | 6.39%269.58 | 19.90%219.04 | -58.86%157.67 | -27.09%137.46 | 7.68%1.01K | -6.67%253.38 | -22.44%182.68 | 79.21%383.23 |
Diluted earnings per share | 98.84%272.39 | -22.18%781.2 | 6.42%268.74 | 19.93%218.34 | -58.83%157.13 | -27.00%136.99 | 7.79%1K | -6.55%252.52 | -22.34%182.06 | 79.37%381.62 |
Dividend per share | 0 | -21.97%393 | 12.39%245 | 0 | -48.19%148 | 0 | 7.70%503.6667 | -13.95%218 | 0 | 33.28%285.6667 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |